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Background: Since the introduction of endovascular aneurysm repair (EVAR), long-term follow-up studies reporting
single-device results are scarce. In this study, we focus on EVAR repair with the Talent stent graft (Medtronic, Santa Rosa, Calif).
Methods: Between July 2000 and December 2007, 365 patients underwent elective EVAR with a Talent device. Patient
data were gathered prospectively and evaluated retrospectively. By American Society of Anesthesiologists category, 74%
were categories III and IV. Postoperative computed tomography (CT) scanning was performed before discharge, at 3, 12
months, and yearly thereafter. Data are presented according to reporting standards for EVAR.
Results: The mean proximal aortic neck diameter was 27 mm (range, 16-36 mm), with a neck length <15 mm in 31% (data
available for 193 patients). Deployment of endografts was successful in 361 of 365 patients (99%). Initially, conversion to
laparotomy was necessary in four patients. Primary technical success determined by results from computed tomography (CT)
scans before discharge was achieved in 333 patients (91%). Proximal type I endoleaks were present in 28 patients (8%) during
follow-up, and 14of these patients needed additional treatment for type I endoleak. The 30-daymortality for thewholeTalent
group was 1.1% (4 of 365). Follow-up to 84 months is reported for 24 patients. During follow-up, 122 (33%) patients died;
in nine, death was abdominal aortic aneurysm (AAA)-related (including 30-day mortality). Kaplan-Meier estimates revealed
primary clinical success rates of 98% at 1 year, 93% at 2 years, 88% at 3 years, 79% at 4 years, 64% at 5 years, 51% at 6 years, and
48% at 7 years. Secondary interventions were performed in 73 of 365 patients (20%). Ten conversions for failed endografts
were performed. Life-table yearly risk for AAA-related reintervention was 6%, yearly risk for conversion to open repair was
1.1%, yearly risk for total mortality was 8.9%, and yearly risk for AAA-related mortality was 0.8%.
Conclusion: Initially, technical success of endovascular aneurysm repair (EVAR) using the Talent endograft is high, with
acceptable yearly risk for AAA-related mortality and conversion. However, a substantial amount of mainly endovascular
reinterventions is necessary during long-term follow-up to achieve these results. ( J Vasc Surg 2011;53:293-8.)
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iEndovascular aneurysm repair (EVAR) is widely accepted
as an alternative for open repair. EVAR has proven to be a less
invasive procedure compared with conventional, open repair
surgery, with shorter procedure duration, reduced blood loss,
shorter hospital stay, and significantly lower 30-day mortality
rate.1,2 The drawback of EVAR is that secondary interven-
tions are needed mainly to treat endoleaks, migration, graft
disconnection, stent fractures, and graft thrombosis. Since the
introductionofEVAR,manydevices are nowavailable for use,
and commercially available devices have changed rapidly
throughout the years, with improved flexibility and more
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doi:10.1016/j.jvs.2010.08.078ecure proximal fixation. It is assumed that the ongoing im-
rovements in graft design will lead to better long-term out-
ome and durability. Therefore, long-term follow-up studies
re needed to evaluate the devices, although we have to keep
n mind that long-term follow-up studies include EVAR pro-
edures performed in the beginning of the EVAR area.
n the past, we reported our experience with the AneuRx
Medtronic, Santa Rosa, Calif) stent graft.3,4 The Talent
Medtronic) stent graft is one of themost used devices world-
ide and combines suprarenal fixation with high radial force
nd columnar strength. Long-term results of treatment with
he Talent device are scarce and limited to small study popu-
ations.5,6 In this article, we report the 7-year results of the
alent graft gathered in two tertiary referral vascular medical
enters. Data were collected prospectively and are retrospec-
ively analyzed. Data are presented according to reporting
tandards for EVAR.7
ATIENTS AND METHODS
Patients were included from two hospitals, The St
ntonius Hospital, Nieuwegein, The Netherlands, and
tanford University Hospital, Stanford, California, USA.
etween July 2000 and December 2007, 365 patients
nderwent elective EVAR with the Talent graft. All aneu-
ysms were infrarenal, and aneurysmatic extension to the
liac arteries was not excluded. Patients who were treated
or a ruptured abdominal aortic aneurysm (AAA) were
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February 2011294 Verhoeven et alexcluded from the study. Inclusion for endovascular treat-
ment was based on the individual surgeon’s decision. Exact
data of anatomy and referral conditions were not available
for all patients, but in both medical centers many patients
had been referred by other surgeons after they were turned
down for EVAR at other hospitals because of high-risk
surgery (American Society of Anesthesiologists [ASA] score
3), and/or challenging anatomy (ie, infrarenal angula-
tion 60 degrees, short neck length 15 mm, and 90
degrees iliac tract).
Data from all patients were recorded prospectively in a
vascular database. The prospective data collection was co-
ordinated between the two sites to capture similar data
points, including the time intervals of the computed to-
mography (CT)-scans during follow-up. The database con-
tains patient characteristics, graft characteristics, procedural
characteristics, data concerning hospital stay, and follow-up
data as readmissions, complications, occurrence of en-
doleaks, and all-cause mortality. Surveillance of patients
after EVAR occurred at the outpatient department by
regular clinical examination and CT scanning to rule out
EVAR related complications like endoleaks at regular time
intervals, including before discharge, at 3, 12 months, and
yearly thereafter. Ultrasound and X-rays were not used
routinely for surveillance during the inclusion period of this
study. In case of a negative CT scan but clinical high
suspicion (ie, increase of AAA diameter) magnetic reso-
nance angiography (MRA) with a specific setting for de-
tecting (small) endoleaks or a selective angiography was
performed. A radiologist and a vascular surgeon reviewed
all follow-up CT scans for proper stent graft position,
fixation, aneurysm diameter, and endoleak appearance. In
case of long distance between patient’s home and our
hospital, CT scans were performed locally. Scans were sent
over for reviewing. If a patient did not appear for a regularly
scheduled follow-up visit, the general practitioner was con-
tacted for information about the patient’s condition.
According to the standards for EVAR, the following
parameters of clinical outcome were reported:7
Survival outcomes. Overall survival and 30-day mor-
tality, freedom from AAA-related death, and freedom from
AAA rupture.
Technical success. Technical success relates to peripro-
cedural events that occur from the initiation of the procedure
and extend through the first 24-hour postoperative period.
Primary technical success is defined by an intention-to-treat
basis and requires the successful introduction and deployment
of the device in the absence of surgical conversion or death,
type I or III endoleaks, or graft limb obstruction. A technical
success thus implies the following qualifying details: (1) Suc-
cessful access to the arterial system using a remote site (ie, the
femoral, external iliac, common iliac, or brachiocephalic arter-
ies, with or without use of a temporary or permanent pros-
thetic conduit to access these arteries); (2) Successful deploy-
ment of the endoluminal graft with secure proximal and distal
fixation; (3) Absence of a type I or III endoleak; and (4)
Patent endoluminal graft without significant twist, kinks, or
obstruction. tDefinition of clinical success. Clinical success should
e reported on an intention-to-treat basis and requires suc-
essful deployment of the endovascular device at the intended
ocation without death as a result of aneurysm-related treat-
ent, type I or III endoleaks, graft infection or thrombosis,
neurysm expansion (increase of native aneurysm diameter
5mm, or AAA volume5%), aneurysm rupture, or conver-
ion to open repair. Moreover, the presence of graft dilatation
f 20% by diameter, graft migration, or a failure of device
ntegrity classifies a case as a clinical failure.
Primary clinical success is clinical success without the
eed for an additional or secondary surgical or endovascu-
ar procedure. Assisted primary or secondary clinical success
s clinical success achieved with the use of an additional
ndovascular or surgical procedure.
Statistical analysis. Data were analyzed using the
PSS 13.0 statistical software (SPSS Inc, Chicago, Ill).
aplan-Meier curves and life tables were created with SPSS.
e used nonparametric tests for continuous variables
Mann-Whitney test, Kruskal-Wallis test) and 2 and the
isher exact test for categoric variables. When significant
ifferences were found with the Kruskal-Wallis test, Dunn’s
ost hoc test was applied. Additionally, binary logistic
egression analyses were used for multiple testing. Values of
 .05 were considered statistically significant.
ESULTS
Patient baseline characteristics are reported in Table I.
ean follow-up was 40 months (range, 1-106 months). For
able I. Patient baseline characteristics
ariable Mean (range) SD
ge, year 74 (52-94) 7.7
roximal graft diameter, mm 30 (24-36) 3.4
aximum AAA diameter, mm 61 (31-125) 12
eck diameter, mm 27 (16-35) 3.4
eck length, mm 26 (6-77) 14
reop creatinine, mol/L 107 (44-577) 48
ospital LOS, days 5.3 (1-67) 7
ollow-up, months 40 (1-106) 26
No. %
ortic neck length 15 mm 60/193 31
eck angulation 60° 20/101 20
eck diameter 30 mm 72/257 28
atients at each center
Stanford 136 37
St. Antonius 229 63
Bifurcated graft 318 87
ortic-monoiliac graft 40 11
ube graft 7 2
raft diameter 32 mm 86/195 44
oiling hypogastric artery 27 7
SA classes III and IV 270 74
ale 326 88
AA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiol-
gists; LOS, length of stay; SD, standard deviation.his study, we report follow-up to 84 months for 24 patients.
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Volume 53, Number 2 Verhoeven et al 295Technical success. Deployment of endografts was
successful in 361 of 365 patients (99%). Initially, four
patients required conversion to laparotomy. One conver-
sion was to solve a large preoperative distal migration of the
just placed stent graft in a patient with a large angulated
neck, and in three patients, it was impossible to introduce
the main device despite endovascular percutaneous trans-
luminal angioplasty (PTA) procedures of the common iliac
arteries. Primary technical success, based on results from
CT scans before discharge, was achieved in 333 patients
(91%). Primary proximal type I endoleaks were present in
28 patients (8%), and 14 (50%) of these 28 needed addi-
tional treatment during follow-up. The median time to
treatment was 13 months. Treatment for these persistent
primary type I endoleaks was; 8 proximal extension cuffs, 2
uni-iliac aortic stent grafts (AUI), 3 aortic neck plications,
and 1 conversion to open repair. Causes of primary type I
endoleak were: suboptimal placement in four, migration in
seven, three suboptimal stent graft appositions. In 10 pa-
tients, type I endoleak resolved spontaneously within a
maximum of 9 months after appearance, with no migration
or enlargement of the native aneurysm during follow-up. In
these patients follow-up with CT scan was intensified to
3-month intervals. No significant difference was deter-
mined between the limited numbers of patients with and
without a spontaneous seal of a proximal type I endoleak in
terms of neck angulation, diameter, and neck length. De-
tails of extent of proximal neck thrombus and calcification
were not recorded.
Four patients, with an early type I endoleak, died soon
after the initial operation of non-AAA related causes (two
of cardiac failures, one of multiorgan failure, and one of
pneumonia).
Survival. Outcome is presented in Table II, including
Table II. Thirty-day and long-term outcomes
Outcome No. %a
30-day outcome
30-day mortality 4 1.1
Successful graft deployment 361 99
Primary technical success 332 91
Long-term outcome
Mortality
Overall 122 33.4
Aneurysm-related, including 30-
day
9 2.5
Cardiac 46 12.6
Pulmonary 18 4.9
Carcinoma 13 3.6
Renal 6 1.6
Unknown 19 5.2
Other 11 3.0
Aneurysm rupture during follow-up 4 1.1
Explantation of Talent by laparotomy 10 2.7
Median follow-up
Primary clinical success 261 71
Assisted primary clinical success 296 81
aPercentage of all included patients (365).AAA-related mortality and all-cause mortality. Of the 365 catients overall, 122 (33%) died during follow-up. Esti-
ated overall survival at 84 months by Kaplan-Meier curve
as 50.4% (Fig 1).
The freedom of AAA-related death is presented as a
aplan-Meier survival curve (Fig 2). The Kaplan-Meier
stimate for freedom of AAA-related death was 92% at 84
onths. Nine AAA-related deaths (2.5%) occurred during
ollow-up. Four patients (1.1%) died within the first 30 days
above-mentioned). The other five patients died of compli-
ig 1. Survival curve for all-cause mortality during follow-up.
tandard errors of displayed data on curves did not exceed 10%.
ig 2. Survival curve for abdominal aortic aneurysm (AAA) re-
ated mortality during follow-up. Standard errors of displayed data
n curves did not exceed 10%.ations of secondary interventions. One patient had non-
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February 2011296 Verhoeven et alsuccessful treatment of a type I endoleak. Eventually, the
AAA ruptured and the patient died during open repair. The
other patient underwent an open procedure after compli-
cated femorofemoral crossover bypass and died due to
myocardiac infarction in the ICU department. The other
three patients, ASA class IV, died of rupture after unsuc-
cessful secondary interventions for endoleaks and migra-
tion.
Four aneurysm ruptures (1.1%) occurred during follow-up.
At 84 months, the Kaplan-Meier estimate for rupture-free
survival is 96.5%.
Clinical success. Primary clinical success was achieved
in 261 of 365 patients (71.5%) at a mean follow-up of 40
months. Data are displayed in Fig 3. Kaplan-Meier esti-
mates revealed primary clinical success rates of 98% at 1
year, 93% at 2 years, 88% at 3 years, 79% at 4 years, 64% at
5 years, 51% at 6 years, 48% at 7 years, and 46.9% at 84
months. Primary-assisted clinical success rate was 81% (296
of 365) at a mean follow-up of 40 months, with a Kaplan-
Meier estimate of 64.1% at 84months. For the 104 patients
who did not meet the criteria for primary clinical success,
73 patients underwent 73 additional procedures and 14
secondary procedures. An overview of the indications for
reinterventions and the procedures performed are reported
in Table III. The 14 secondary interventions comprised 4
conversions to laparotomy, 4 proximal extension cuffs, 2
femorofemoral crossover bypasses, 1 embolectomy, 1 PTA,
1 aortic neck wrapping, and 1 exploration to staunch a
hemorrhage. In only two patients with endograft limb
occlusions was thrombolysis used. In most of the patients
with endograft (limb) occlusions an additional morpho-
logic problem with the endograft limb was seen, like kink-
Fig 3. Primary clinical success presented as a survival curve during
follow-up. Standard errors of displayed data on curves did not
exceed 10%.ing or migration. These problems had to be treated with tenewed stent grafts, or femorofemoral crossover bypass
nd were combined with open thrombectomy, instead of
hrombolysis.
The remaining 31 of the 104 patients did not have a
eintervention. Of the patients who did not receive addi-
ional treatment, 1 patient refused therapy for a type I
ndoleak, 2 had minor stent graft migrations, 1 had a small
ype III endoleak, and 4 patients died within 30 days.
wenty-three patients had AAA expansion5mmwithout
resence of endoleaks or stent graft migration. These pa-
ients are in extensive follow-up with late phase CT and
RA scanning to detect the possible cause of AAA expan-
ion.
Patients who did not reach clinical success criteria were
ompared with primary clinical successful patients. Com-
ared were baseline AAA diameter, proximal aortic neck
ength, proximal aortic neck diameter, proximal endograft
ize (32 mm vs 32 mm), ASA class, graft length and
onfiguration (bifurcation, AUI, tube graft), and age.
ann-Whitney testing did not reveal statistical signifi-
ances between the groups, including graft configuration
nd proximal diameter. However, there was a tendency
P  .07) for increasing age, larger AAA diameters, and
horter proximal aortic necks among patients who did not
eet clinical success. Additionally, binary logistic regres-
ion analyses revealed larger AAA diameter was associated
ith clinical failures (P  .05).
Ten open conversions for failed endografts were per-
ormed, including initial conversions. The life-table yearly
isk for AAA-related reintervention was 6%, yearly risk for
onversion was 1.1%, and yearly risk for AAA-related mor-
able III. Indications for reinterventions and type of
nterventions
ariable Cases (No.)
ndications for reinterventions
Migration 11
Type I endoleak 21
Type II endoleak 9
Type III endoleak 1
Graft thrombosis/kinking 16
Infection 4
Postoperative hemorrhage 1
Rupture of aneurysm 1
Iliac stenoses 3
Renal artery stenoses 3
Unspecified 3
nterventions
Additional cuff placement 18
Coiling 8
Thrombolysis/thrombectomy/PTA 20
Femfem crossover bypass 5
Laparotomy, endograft explant 6
Abscess drainage 2
Staunch hemorrhage 1
Aortic monoiliac endoprosthesis 6
Surgical control of lumbar endoleak 1
Aortic neck wrapping 5
TA, Percutaneous transluminal angioplasty.ality was 0.8%.
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EVAR is widely accepted as a treatment for AAA. The
long-term data of the Comparison of Endovascular Aneu-
rysm Repair with Open Repair in Patients with Abdominal
Aortic Aneurysm (EVAR-1) trial and the Dutch Random-
ized Endovascular AneurysmManagement (DREAM) trial
were recently published.8,9 The long-term all-cause mor-
tality did not differ between open surgery and the EVAR
group. However, there was an initial benefit for EVAR due
to a lower AAA-related mortality. EVAR-1 and other ran-
domized trials were not designed to investigate the differ-
ent EVAR devices, endograft capabilities and limitations,
and device specific results.1,2 In daily practice, it is therefore
useful that long-term data of frequently used EVAR de-
vices, like the Talent device, are available.
Long-term results with other stent grafts have been
published in the recent years. In 2009, Bos et al described
their 5-year results with the Gore Excluder (W. L. Gore,
Flagstaff, Ariz) stent graft.10 They showed an excellent
long-term result with a 70% survival at 5-years with a 13%
reinterventions rate and no AAA ruptures during follow-
up. Abbruzzese et al analyzed the long-term device specific
outcomes of the Cook Zenith (William A. Cook PTY LTD,
Brisbane, Australia), Gore Excluder, and Medtronic An-
euRx stent grafts and published comparable long-term
outcomes.11 Overall 5-year survival rate was 61% with a
reintervention rate of 20% and a 5-year AAA rupture rate of
1.1%. However, data are difficult to compare since the
criteria for reporting standards for EVAR, published by
Chaikof et al, are not used consequently.
Long-term results of the Talent graft are limited to a
few studies.5,12 Through the years, indications for EVAR
have changed. In the beginning, EVAR was more likely to
be used as a therapy in patients who were unfit for open
surgery. The studied population in this report also had
severe comorbidities, reflected by the ASA classification
presented in Table I. Besides high number of ASA 3 and
four patients, a substantial part of patients was treated with
EVAR in presence of challenging anatomy of the proximal
neck (neck angulation 60 degrees, neck diameter 30
mm or neck length15 mm, Table I). The overall mortal-
ity rate reported for this cohort is comparable with other
series.12,13 Although long-term all-cause mortality is high
in the current study, the 30-day mortality data of our
cohort are good and even lower than in other series for
EVAR and substantially lower than open repair.1,2,8,12 The
EVAR-1 and DREAM trials showed an operative (30-day)
mortality rate for the open-repair group of 4.7 and 4.6%,
respectively.1,2 Aneurysm-related death and rupture in our
study were limited and at least comparable to results re-
ported in the randomized trials and registries.13-15 How-
ever, some under-registration of ruptured AAA could have
occurred because postmortem examinations were not reg-
ularly performed.
Implantation and deployment of the graft was success-
ful in 99% of the patients. Despite the Talent graft design
with the ability of transrenal fixation by a 15-mm-long encovered stent, primary technical success was still limited
o 91%, mainly due to type I proximal endoleaks. An
xplanation for this could be the treating of a considerable
umber of patients with challenging AAA morphology,
uch as large and angulated (60 degrees) aortic necks.
etailed information about aortic neck length and diame-
ers were available for 193 patients and information about
eck angulation in 101 patients. The Talent graft was used
o treat 60 patients with neck length 15 mm, which is
ikely to be a risk for a proximal type I endoleak. The
resence of a perioperative detected type I endoleak is
linically relevant.
Perioperative additional procedures to solve a type I
ndoleak discovered on the completing angiography must
e attempted. However, as described in the Results section,
ome endoleaks will spontaneously seal. In this cohort, 14
f 28 patients (50%) needed additional treatment for per-
istent type I endoleak during follow-up.
If no migration was seen, no AAA diameter or volume
rowth was noticed, and the position of the proximal
ndograft was optimal with regard to the lowermost renal
rtery, a watchful waiting policy was applied. In case of
ndograft migration with 1-cm fixation left, native AAA
iameter, or volume growth, elective endovascular reinter-
ention was scheduled. In most of the patients who needed
n open reintervention procedure the intervention was
ostponed after persistent EVAR-related complications
ere diagnosed at a second control CT scan at 6 or 9
onths.
During follow-up, clinical success was accomplished in
lmost half of the patients. A substantial number of patients
nderwent additional procedures. Most of these proce-
ures were performed endovascularly, which limits patient
omorbidity. Besides the mentioned number of endoleak
roblems, graft thrombosis and kinking were also issues. At
he completion angiography of all patients, no kinking of
he endograft limbs was predictable. Our data are consis-
ent with other publications.5,12 During the follow-up
ears, reinterventions had to be performed consistently
hrough all years. Regarding the Kaplan-Meier curve, a
ubstantial increase in reinterventions could be observed in
ater years of follow-up. Therefore, regular and long-term
linical and radiologic surveillance is mandatory after a
uccessful EVAR procedure.
This study is not without some limitations.
Due to the retrospective character of this study, we do
iss anatomical data such as the preoperative proximal
uprarenal and infrarenal neck angulation in a substantial
art of the patients and the existence of aneurysmal degen-
ration of the common iliac arteries.
Similar to all long-term follow-up studies for EVAR, we
ncluded patients over a long time interval. This means that
substantial number of patients were treated in the early
ays of our experience with the Talent device. Although we
id not observe a decrease in EVAR-related complications
ver the years, there have been improvements in experience
f EVAR at both institutions that will have been of influ-
nce in the study outcome. On the other hand, in both
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other devices before the Talent stent graft had been intro-
duced.
The graft itself has evolved over the years (improved
proximal fixation, a lower profile, and available in larger
diameters up to 36 mm). These refinements in graft design
could have influenced our results over the years.
Moreover, as the study progressed, the treatment
boundaries were extended over the years, and patients with
shorter and wider necks and increased angulation were
treated, sometimes with violation of the instructions for
use. This counteracts with the improvement in stent graft
fixation characteristics.
One should also be aware that most of the included
patients were referred by other hospitals and were denied
for open as well for EVAR on bases of their anatomic
characteristics and comorbidity in these (less experienced)
centers, which might have introduced a selected patient
group.
CONCLUSIONS
In this cohort with a high number of patients with
severe comorbidity, overall mortality post-EVAR was sub-
stantial during follow-up. Technical success and clinical
outcome are comparable to other manuscripts focusing on
use of single EVAR devices. The current study showed
(again) that the policy of treating higher risk patients with a
suboptimal AAA anatomy for EVAR repair has its draw-
backs including regularly and persistent follow-up and sub-
stantial need for reinterventions, which increases with
follow-up duration.
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